莆田招聘

RESPONSIBILITIES
The Senior Executive, Business Development will be an advisor to and collaborator with the Senior Management Team, and will be responsible for leading strategic business development initiatives. She / He will work closely with the CEO,VP,Corporate Development, investors, and other senior leaders, and will assess the company's business development strategy and performance to further drive future innovation and market growth. Other duties and responsibilities include:
Define new external opportunities and work with the senior leadership team to perform assessments, and lead potential transactions.
Develop strategic framework to analyze the company's existing business as well as new market opportunities (partner, acquire, build).
Lead strategic BD efforts, including scanning the market, establishing target lists, summarizing key targets, fit with company strategy, estimates of target size and market size/growth.
Responsible for leading negotiation teams and closing deals.
Review and provide strategic recommendations regarding company BD activities, and build a proactive, robust BD environment.
Prospect and build new business relationships with clients, suppliers, vendors, and technology partners.
Define, articulate, and lead business development opportunities including the presentation of company summaries, scientific, commercial, and financial value drivers to senior leadership team.
Plans, organizes, and provides market intelligence, communications, processes, and leadership to achieve operational, tactical, and business development objectives.
Lead due diligence and deal teams, establishing partnerships and acquiring/divesting assets while including financial forecasting, analysis, modeling, and implementation planning.
Provide sales support on behalf of Business Development Unit, for example handling small project enquiries, from enquiry through to successful conclusion.
Identify potential problems and alert senior management of any possible adverse impact. Recommending new opportunities; recommending profit and service improvements.
Establishing and maintaining industry and client contacts for continuing good relations and business opportunity development.
Design and maintain a business development dashboard for the senior management team. Developing and maintaining client profiles including updating contacts management system.
DESIRED SKILLS AND EXPERIENCE
QUALIFICATIONS
Requires MBA and science degree with a minimum of eight years business development experience in a biotech/pharmaceutical environment globally.
Prior experience in dealing with transactions, corporate partners and in negotiating and completing agreements is required.
A thorough understanding of the drug development and commercialization process.
Have a good understanding of biologics' production environment; a thorough understanding of due diligence, asset valuation, alliance integration and portfolio management.
Strong scientific and business acumen, excellent organizational and analytical skills are required.
Good ability to interpret customer requirements precisely and to communicate with development and manufacturing personnel.
Must be a team player, strong interpersonal skills and demonstrated ability to lead and participate effectively in cross-functional teams and willing to/capable of operating in a fast paced, demanding environment.
Other requirements may include extensive contacts in the biotechnology/pharmaceutical industry relevant to the acquisition or licensing of targets.
Good ability to coach others and drive for business results.
Strong writing, oral communication, and presentation skills in both English and Chinese.

    烟台荣昌制药股份有限公司创建于1993年3月，位于烟台市经济技术开发区北京中路56号。经过20多年的发展，目前，公司下设荣昌制药（淄博）有限公司、北京荣昌药物研究院、烟台立达医药有限公司、荣昌生物制药（烟台）有限公司、烟台业达国际生物医药创新孵化中心有限公司等子公司，发展成为集研发、生产、销售、服务为一体，横跨现代中药、生物制药、生物药物研发和生产服务（CDMO）、生物医药企业和项目孵化四大领域的现代化制药企业。
荣昌制药及其旗下公司共有药品生产批准文号90余个，主要为中成药。其中，拳头产品为肛泰和甜梦两大系列。另外，健脑补肾丸、大青叶系列、仕卫、小儿定喘口服液、坤宁口服液、复方荆芥熏洗剂等产品也在市场上倍受青睐。
荣昌制药紧跟全球药物发展潮流，1997年，在国内率先进入生物新药创制领域。2005年，公司与留美科学家合作，成功地研发出了抗肿瘤一类生物新药重组人血管内皮抑制素（商品名：恩度）。该药的上市，标志着中国在血管抑制剂类抗肿瘤药物的研发走在了世界前列。2008年，公司与留美科学家房健民教授共同创办烟台荣昌生物工程有限公司，后更名为“荣昌生物制药（烟台）有限公司”，致力于生物创新药物的研发创制及产业化。目前，公司拥有8个国家创新生物新药，其中1项列入国家“863”计划，7项进入国家“新药创制”重大专项。其中，用于治疗系统性红斑狼疮、类风湿性关节炎等自身免疫疾病的生物创新药物“泰爱”已进入Ⅱ、Ⅲ期临床研究；用于治疗胃癌、乳腺癌等肿瘤疾病的RC48已经获得国家食品药品监督管理总局下发的临床批件，是我国率先进入人体临床试验的ADC药物，标志着我国在ADC药物研发领域获得了突破性进展。
    在未来，公司将以“用科学提高生命质量”为己任，以“做中国***的制药公司”为目标，针对危害人类健康的重大疾病和常见病、多发病，通过研发、生产和销售疗效确切、质量可靠、价格合理的药品，为患者解除病痛，延长寿命，提高生命质量，实现公司价值的***化。
荣昌人的辛勤付出，得到了社会的认可。公司先后被各级政府组织认定为高新技术企业、国家火炬计划重点高新技术企业、国家（企业）创新药物孵化基地、国家综合性新药研发技术大平台（山东）产业化示范企业、山东省抗体药物工程研究中心、山东省工程技术研究中心、山东省企业技术中心、山东省中药现代化科技示范企业、山东省制造业信息化示范企业等。
集团在管理方面，坚持以人为本，注重人才培养及梯队建设，为员工提供完善的福利待遇、广阔的发展机会与平台、专业的培训及深造机会。在未来，集团将以“用科学提高生命质量”为己任，以“做中国***的制药公司”为目标，针对危害人类健康的重大疾病和常见病、多发病，通过研发、生产和销售疗效确切、质量可靠、价格合理的药品，为患者解除病痛，延长寿命，提高生命质量，实现公司价值的***化。
网 址： *****************.
微信号：请搜索“荣昌制药”及“荣昌人”公众号，关注公司信息
公司地址：烟台经济技术开发区北京中路56号